COCP 2,09$ (+56%)


Seite 1 von 1
Neuester Beitrag: 30.03.20 12:22
Eröffnet am: 25.02.20 16:17 von: Vassago Anzahl Beiträge: 4
Neuester Beitrag: 30.03.20 12:22 von: Bezugs_Rec. Leser gesamt: 298
Forum: Börse   Leser heute: 2
Bewertet mit:
1


 

5159 Postings, 1032 Tage VassagoCOCP 2,09$ (+56%)

 
  
    #1
1
25.02.20 16:17

Corona-Hype

  • Umsatz 0,5 Mio. $ (alles für Q3/19)
  • Verlust 1,8 Mio. $
  • Cash 6 Mio. $
  • MK 87 Mio. $

https://www.cocrystalpharma.com/news/...-third-quarter-2019-financial

Dann kam Corona, der Kurs stieg, das Management zog ein Offering durch:

  • 3,5 Mio. neue Aktien zu je 0,63$ = 2,2 Mio. $

https://www.cocrystalpharma.com/news/...ounces-closing-of-2-2-million

Mal sehen, wann die nächste Kapitalerhöhung kommt...

 

1174 Postings, 570 Tage up088-k News raus

 
  
    #2
04.03.20 16:05
$COCP. Current Report Filing (8-k)

http://ih.advfn.com/stock-market/NASDAQ/.../current-report-filing-8-k

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 4, 2020

Cocrystal Pharma, Inc.

(Exact name of registrant as specified in its charter)



Delaware 001-38418 35-2528215
(State or other Jurisdiction

of Incorporation)


(Commission

File Number)


(IRS Employer

Identification No.)



19805 N. Creek Parkway

Bothell, WA

98011
(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (786) 459-1831


(Former name or former address, if changed since last report.):

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).


§
Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class Trading Symbol(s) Name of each exchange on which registered
Common Stock COCP
The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)


Item 7.01 Regulation FD Disclosure.



On March 4, 2020, Cocrystal Pharma, Inc. (the “Company”) posted a presentation to its website. A copy of the Company’s presentation is being furnished as Exhibit 99.1 hereto.



The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, or the Exchange Act.



Item 9.01. Financial Statements and Exhibits.

(d)
Exhibit No.


Description.


99.1 Investor Presentation dated March 2020


SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Cocrystal Pharma, Inc.

Dated: March 4, 2020 By: /s/ James Martin
James Martin
Chief Financial Officer  

58 Postings, 47 Tage GalacticaPlans to Advance Coronavirus Program

 
  
    #3
09.03.20 18:38
March 6, 2020
https://finance.yahoo.com/news/...ounces-plans-advance-210110576.html

... Given the global threat of COVID1-9, our primary goal is to advance our Coronavirus program into preclinical development.  

717 Postings, 1659 Tage Bezugs_RechtNEWS eben raus collaboration with Merck

 
  
    #4
30.03.20 12:22
Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020

http://www.globenewswire.com/news-release/2020/03/...es-for-2020.html  

   Antwort einfügen - nach oben

  1 Nutzer wurde vom Verfasser von der Diskussion ausgeschlossen: Seefalcon